[Targeting of membrane receptor tyrosine kinases: is there resistance in the HER?].

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Bulletin du Cancer

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 15544994
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies.

  2004cited by this paper
• Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.

  2004cited by this paper
• Mutation of Threonine 766 in the Epidermal Growth Factor Receptor Reveals a Hotspot for Resistance Formation against Selective Tyrosine Kinase Inhibitors*

  2003cited by this paper
• Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.

  2003cited by this paper
• [Future perspectives. From basic research to the development of new therapies aimed at the inhibition of the different stages of signal transduction: applications in breast cancer].

  2003cited by this paper
• Targeting of cells expressing wild‐type EGFR and type‐III mutant EGFR (EGFRvIII) by anti‐EGFR MAb ICR62: A two‐pronged attack for tumour therapy

  2003cited by this paper
• Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.

  2003cited by this paper
• Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.

  2003cited by this paper
• [Role of the combination of trastuzumab and taxanes in the therapeutic management of cancer of the breast: from preclinical data to clinical application].

  2003cited by this paper
• Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer

  2003cited by this paper
• Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

  2003cited by this paper
• Development of the epidermal growth factor receptor inhibitor OSI-774.

  2003cited by this paper
• A Carboxyl-terminal Mutation of the Epidermal Growth Factor Receptor Alters Tyrosine Kinase Activity and Substrate Specificity as Measured by a Fluorescence Polarization Assay*

  2003cited by this paper
• Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.

  2002cited by this paper
• Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies

  2002cited by this paper
• Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).

  2002cited by this paper
• Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

  2002cited by this paper
• In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines.

  2002cited by this paper
• Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts.

  2002cited by this paper
• Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (‘Iressa’)

  2002cited by this paper
• ZD1839 (Iressa): what's in it for the patient?

  2002cited by this paper
• Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.

  2002cited by this paper
• Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

  2002cited by this paper
• Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway.

  2002cited by this paper
• Rat Muc4 (sialomucin complex) reduces binding of anti‐ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance

  2002cited by this paper
• [Update on . . . the proteasome inhibitor PS341].

  2002cited by this paper
• Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor.

  2002cited by this paper
• Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

  2002cited by this paper
• Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.

  2001cited by this paper
• The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

  2001cited by this paper
• Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

  2001cited by this paper
• Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.

  2001cited by this paper
• High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo.

  2001cited by this paper
• Truncated ErbB2 receptor enhances ErbB1 signaling and induces reversible, ERK‐independent loss of epithelial morphology

  2001cited by this paper
• Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.

  2001cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• CI-1033, a pan-erbB tyrosine kinase inhibitor.

  2001cited by this paper
• [Breast cancer and herceptin].

  2000cited by this paper
• ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27Kip1-Cdk2 Complex Formation: Receptor Overexpression Does Not Determine Growth Dependency

  2000cited by this paper
• Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression.

  2000cited by this paper
• [Zd 1839 "Iressa"].

  2000cited by this paper
• Expression of c‐erbB receptors, heregulin and oestrogen receptor in human breast cell lines

  2000cited by this paper
• Modulation of Epidermal Growth Factor Receptor Gene Transcription by a Polymorphic Dinucleotide Repeat in Intron 1*

  1999cited by this paper
• Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

  1999cited by this paper
• Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

  1999cited by this paper
• [Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene?].

  1999cited by this paper
• In vitro modulation of cyst formation by a novel tyrosine kinase inhibitor.

  1999cited by this paper
• The epidermal growth factor receptor and its inhibition in cancer therapy.

  1999cited by this paper
• Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members.

  1999cited by this paper
• Epidermal growth factor receptor relocalization and kinase activity are necessary for directional migration of keratinocytes in DC electric fields.

  1999cited by this paper
• Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase

  1999cited by this paper
• Constitutive Activation of Phosphatidylinositol 3-Kinase by a Naturally Occurring Mutant Epidermal Growth Factor Receptor*

  1998cited by this paper
• Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.

  1998cited by this paper
• Differential endocytic routing of homo‐ and hetero‐dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers

  1998cited by this paper
• Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

  1998cited by this paper
• Soluble HER‐2/neu neutralizes biologic effects of anti‐HER‐2/neu antibody on breast cancer cells in vitro

  1997cited by this paper
• Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors.

  1996cited by this paper
• Polyubiquitination and Proteasomal Degradation of the p185c-erbB-2 Receptor Protein-tyrosine Kinase Induced by Geldanamycin*

  1996cited by this paper
• p120 Is a Cytosolic Adapter Protein That Associates with Phosphoinositide 3-Kinase in Response to Epidermal Growth Factor in PC12 and Other Cells (*)

  1996cited by this paper
• Epidermal growth factor-related peptides and their receptors in human malignancies.

  1995cited by this paper
• Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity.

  1994cited by this paper
• A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells

  1993cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper

• HER2 STATUS BREAST CANCER IN A POPULATION OF WESTERN ALGERIA

  2013cites this paper
• The role of ubiquitin-proteasome system in glioma survival and growth

  2013cites this paper
• Inhibiteurs de tyrosine kinase utilisés dans les tumeurs solides : proposition de fiches d'utilisation pratique destinées à l'équipe officinale

  2011cites this paper
• Cellular response to cetuximab in PTEN-silenced head and neck squamous cell carcinoma cell line.

  2010cites this paper
• [Targeted therapies: the question of target detection and evaluation].

  2007cites this paper
• [Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].

  2007cites this paper
• p95HER-2 Predicts Worse Outcome in Patients with HER-2-Positive Breast Cancer

  2006cites this paper
• [Targeted biotherapies in digestive oncology: a new era in therapeutic management?].

  2005cites this paper